Effect of nicorandil on proteinuria in well controlled hypertensive patients

Tsung-Ming Lee, Nen Chung Chang

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

OBJECTIVE: Proteinuria is an important risk factor for cardiovascular and renal morbidity and mortality. The effect of nicorandil on proteinuria in hypertensive patients well controlled by antihypertensive agents containing a low dose of valsartan has not been studied. PATIENTS AND METHODS: A total of 136 proteinuric (300-3000 mg/day), valsartan-treated hypertensive patients with blood pressure less than 140/90 mmHg were randomized into three groups to receive placebo, isosorbide dinitrate (30 mg/day), or nicorandil (15 mg/day) for 6 months. RESULTS: The average dose of valsartan given to the patients was similar in the three groups. Creatinine clearance remained stable throughout the study in the three groups. Nicorandil, but not isosorbide dinitrate, significantly reduced proteinuria by 44% after 6 months (P <0.0001). Urinary endothelin-1 levels significantly decreased after administration of nicorandil (P = 0.002), whereas placebo and isosorbide dinitrate had no effect. Urinary excretion of endothelin-1 was significantly correlated with improvement in urinary protein excretion in nicorandil-treated patients (r = 0.69, P <0.0001). The urinary excretion of retinol-binding protein decreased after nicorandil administration, probably reflecting an improvement in tubular function. In contrast, the urinary excretion of immunoglobulin G did not change significantly throughout the study in the three groups. Multivariate analysis revealed that proteinuria was only significantly correlated with the use of nicorandil (model adjusted r = 0.35, P <0.0001). CONCLUSION: The addition of nicorandil to treatment for patients with well controlled hypertension may have an additive effect on reducing proteinuria independent of hemodynamics and nitric oxide effects, possibly through inhibiting renal endothelin-1 synthesis and improving tubular function.

Original languageEnglish
Pages (from-to)618-625
Number of pages8
JournalJournal of Hypertension
Volume27
Issue number3
DOIs
Publication statusPublished - Mar 2009

Fingerprint

Nicorandil
Proteinuria
Valsartan
Isosorbide Dinitrate
Endothelin-1
Placebos
Kidney
Retinol-Binding Proteins
Antihypertensive Agents
Creatinine
Nitric Oxide
Multivariate Analysis
Immunoglobulin G
Hemodynamics
Blood Pressure
Hypertension
Morbidity
Mortality

Keywords

  • ATP-sensitive potassium channels
  • Endothelin-1
  • Hypertension
  • Proteinuria

ASJC Scopus subject areas

  • Internal Medicine
  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Effect of nicorandil on proteinuria in well controlled hypertensive patients. / Lee, Tsung-Ming; Chang, Nen Chung.

In: Journal of Hypertension, Vol. 27, No. 3, 03.2009, p. 618-625.

Research output: Contribution to journalArticle

@article{c8aee7e3995b4cdda7620832ade494e2,
title = "Effect of nicorandil on proteinuria in well controlled hypertensive patients",
abstract = "OBJECTIVE: Proteinuria is an important risk factor for cardiovascular and renal morbidity and mortality. The effect of nicorandil on proteinuria in hypertensive patients well controlled by antihypertensive agents containing a low dose of valsartan has not been studied. PATIENTS AND METHODS: A total of 136 proteinuric (300-3000 mg/day), valsartan-treated hypertensive patients with blood pressure less than 140/90 mmHg were randomized into three groups to receive placebo, isosorbide dinitrate (30 mg/day), or nicorandil (15 mg/day) for 6 months. RESULTS: The average dose of valsartan given to the patients was similar in the three groups. Creatinine clearance remained stable throughout the study in the three groups. Nicorandil, but not isosorbide dinitrate, significantly reduced proteinuria by 44{\%} after 6 months (P <0.0001). Urinary endothelin-1 levels significantly decreased after administration of nicorandil (P = 0.002), whereas placebo and isosorbide dinitrate had no effect. Urinary excretion of endothelin-1 was significantly correlated with improvement in urinary protein excretion in nicorandil-treated patients (r = 0.69, P <0.0001). The urinary excretion of retinol-binding protein decreased after nicorandil administration, probably reflecting an improvement in tubular function. In contrast, the urinary excretion of immunoglobulin G did not change significantly throughout the study in the three groups. Multivariate analysis revealed that proteinuria was only significantly correlated with the use of nicorandil (model adjusted r = 0.35, P <0.0001). CONCLUSION: The addition of nicorandil to treatment for patients with well controlled hypertension may have an additive effect on reducing proteinuria independent of hemodynamics and nitric oxide effects, possibly through inhibiting renal endothelin-1 synthesis and improving tubular function.",
keywords = "ATP-sensitive potassium channels, Endothelin-1, Hypertension, Proteinuria",
author = "Tsung-Ming Lee and Chang, {Nen Chung}",
year = "2009",
month = "3",
doi = "10.1097/HJH.0b013e32831cbd73",
language = "English",
volume = "27",
pages = "618--625",
journal = "Journal of Hypertension",
issn = "0263-6352",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Effect of nicorandil on proteinuria in well controlled hypertensive patients

AU - Lee, Tsung-Ming

AU - Chang, Nen Chung

PY - 2009/3

Y1 - 2009/3

N2 - OBJECTIVE: Proteinuria is an important risk factor for cardiovascular and renal morbidity and mortality. The effect of nicorandil on proteinuria in hypertensive patients well controlled by antihypertensive agents containing a low dose of valsartan has not been studied. PATIENTS AND METHODS: A total of 136 proteinuric (300-3000 mg/day), valsartan-treated hypertensive patients with blood pressure less than 140/90 mmHg were randomized into three groups to receive placebo, isosorbide dinitrate (30 mg/day), or nicorandil (15 mg/day) for 6 months. RESULTS: The average dose of valsartan given to the patients was similar in the three groups. Creatinine clearance remained stable throughout the study in the three groups. Nicorandil, but not isosorbide dinitrate, significantly reduced proteinuria by 44% after 6 months (P <0.0001). Urinary endothelin-1 levels significantly decreased after administration of nicorandil (P = 0.002), whereas placebo and isosorbide dinitrate had no effect. Urinary excretion of endothelin-1 was significantly correlated with improvement in urinary protein excretion in nicorandil-treated patients (r = 0.69, P <0.0001). The urinary excretion of retinol-binding protein decreased after nicorandil administration, probably reflecting an improvement in tubular function. In contrast, the urinary excretion of immunoglobulin G did not change significantly throughout the study in the three groups. Multivariate analysis revealed that proteinuria was only significantly correlated with the use of nicorandil (model adjusted r = 0.35, P <0.0001). CONCLUSION: The addition of nicorandil to treatment for patients with well controlled hypertension may have an additive effect on reducing proteinuria independent of hemodynamics and nitric oxide effects, possibly through inhibiting renal endothelin-1 synthesis and improving tubular function.

AB - OBJECTIVE: Proteinuria is an important risk factor for cardiovascular and renal morbidity and mortality. The effect of nicorandil on proteinuria in hypertensive patients well controlled by antihypertensive agents containing a low dose of valsartan has not been studied. PATIENTS AND METHODS: A total of 136 proteinuric (300-3000 mg/day), valsartan-treated hypertensive patients with blood pressure less than 140/90 mmHg were randomized into three groups to receive placebo, isosorbide dinitrate (30 mg/day), or nicorandil (15 mg/day) for 6 months. RESULTS: The average dose of valsartan given to the patients was similar in the three groups. Creatinine clearance remained stable throughout the study in the three groups. Nicorandil, but not isosorbide dinitrate, significantly reduced proteinuria by 44% after 6 months (P <0.0001). Urinary endothelin-1 levels significantly decreased after administration of nicorandil (P = 0.002), whereas placebo and isosorbide dinitrate had no effect. Urinary excretion of endothelin-1 was significantly correlated with improvement in urinary protein excretion in nicorandil-treated patients (r = 0.69, P <0.0001). The urinary excretion of retinol-binding protein decreased after nicorandil administration, probably reflecting an improvement in tubular function. In contrast, the urinary excretion of immunoglobulin G did not change significantly throughout the study in the three groups. Multivariate analysis revealed that proteinuria was only significantly correlated with the use of nicorandil (model adjusted r = 0.35, P <0.0001). CONCLUSION: The addition of nicorandil to treatment for patients with well controlled hypertension may have an additive effect on reducing proteinuria independent of hemodynamics and nitric oxide effects, possibly through inhibiting renal endothelin-1 synthesis and improving tubular function.

KW - ATP-sensitive potassium channels

KW - Endothelin-1

KW - Hypertension

KW - Proteinuria

UR - http://www.scopus.com/inward/record.url?scp=67649518831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649518831&partnerID=8YFLogxK

U2 - 10.1097/HJH.0b013e32831cbd73

DO - 10.1097/HJH.0b013e32831cbd73

M3 - Article

C2 - 19262229

AN - SCOPUS:67649518831

VL - 27

SP - 618

EP - 625

JO - Journal of Hypertension

JF - Journal of Hypertension

SN - 0263-6352

IS - 3

ER -